Mind Medicine (MindMed) (MNMD) Stock Price, News & Analysis

Company Overview

Mind Medicine (MindMed) is a clinical-stage biopharmaceutical company dedicated to developing novel treatments for mental health disorders and addiction through the controlled use of psychedelic-inspired compounds. Established in 2019 and headquartered in New York, MindMed leverages advances in neuroscience to explore molecules such as LSD analogues, ibogaine derivatives and other psychoactive substances. The company’s mission is to address unmet needs in conditions including anxiety, depression, post-traumatic stress disorder and substance use disorders by harnessing the therapeutic potential of these compounds under rigorous clinical protocols.

MindMed’s pipeline includes a range of investigational therapies designed to offer single- or short-course dosing regimens with the goal of achieving sustained clinical benefit. Key programs involve an ibogaine-derived compound targeting opioid withdrawal and dependence, as well as next-generation analogues of lysergic acid diethylamide (LSD) being evaluated for anxiety and addiction treatment. Studies are conducted in compliance with regulatory guidelines, with research sites spanning North America and Europe to advance multiple Phase 2 trials.

The company collaborates with leading academic institutions and research organizations to deepen scientific understanding of psychedelic-assisted therapy. Partnerships with entities such as Imperial College London and Johns Hopkins University support neuroimaging, safety assessments and behavioral studies. MindMed also maintains strategic alliances with contract manufacturing organizations to ensure high-quality production of its proprietary drug candidates under Good Manufacturing Practice standards.

Under the leadership of Chief Executive Officer JR Rahn, MindMed has grown its global footprint with offices in Zurich, London and Vancouver, in addition to its New York headquarters. The executive team combines experience in biotech development, regulatory affairs and psychiatry research, positioning the company to navigate the evolving landscape of psychedelic-based therapeutics and bring innovative mental health treatments to market.

Key Stats

• Today's Range: $7.54 to $7.81
• 50-Day Range: $6.16 to $7.89
• 52-Week Range: $4.70 to $10.44
• Volume: 478,370 shs
• Average Volume: 1.56 million shs
• Market Capitalization: $580.98 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: $25.50
• Consensus Rating: Buy

Mind Medicine (MindMed) Stock Analysis - MarketRank™

Mind Medicine (MindMed) scored higher than 56% of companies evaluated by MarketBeat, and ranked 454th out of 922 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 3.6 / 5
• Analyst Rating: Buy

Consensus Rating

Mind Medicine (MindMed) has received a consensus rating of Buy. The company's average rating score is 3.27, and is based on 8 buy ratings, no hold ratings, and no sell ratings.

Amount of Analyst Coverage

Mind Medicine (MindMed) has only been the subject of 2 research reports in the past 90 days.

Earnings and Valuation

• Score: 0.6 / 5
• Proj. Earnings Growth: Growing

Earnings Growth

Earnings for Mind Medicine (MindMed) are expected to grow in the coming year, from ($1.35) to ($0.74) per share.

Price to Earnings Ratio vs. the Market

The P/E ratio of Mind Medicine (MindMed) is -5.97, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Earnings Ratio vs. Sector

The P/E ratio of Mind Medicine (MindMed) is -5.97, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Book Value per Share Ratio

Mind Medicine (MindMed) has a P/B Ratio of 2.41. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.

Short Interest

• Score: 3.0 / 5
• Short Interest Level: Healthy

Percentage of Shares Shorted

15.20% of the float of Mind Medicine (MindMed) has been sold short.

Short Interest Ratio / Days to Cover

Mind Medicine (MindMed) has a short interest ratio ("days to cover") of 9.3.

Change versus previous month

Short interest in Mind Medicine (MindMed) has recently decreased by 6.03%, indicating that investor sentiment is improving significantly.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

Mind Medicine (MindMed) does not currently pay a dividend.

Dividend Growth

Mind Medicine (MindMed) does not have a long track record of dividend growth.

Sustainability and ESG

• Score: N/A
• Environmental Score: N/A

Percentage of Shares Shorted

15.20% of the float of Mind Medicine (MindMed) has been sold short.

Short Interest Ratio / Days to Cover

Mind Medicine (MindMed) has a short interest ratio ("days to cover") of 9.3.

Change versus previous month

Short interest in Mind Medicine (MindMed) has recently decreased by 6.03%, indicating that investor sentiment is improving significantly.

News and Social Media

• Score: 2.9 / 5
• News Sentiment: 1.18

News Sentiment

Mind Medicine (MindMed) has a news sentiment score of 1.18. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.57 average news sentiment score of Medical companies.

News Coverage This Week

MarketBeat has tracked 3 news articles for Mind Medicine (MindMed) this week, compared to 3 articles on an average week.

Search Interest

Only 15 people have searched for MNMD on MarketBeat in the last 30 days. This is a decrease of 0% compared to the previous 30 days.

MarketBeat Follows

20 people have added Mind Medicine (MindMed) to their MarketBeat watchlist in the last 30 days. This is an increase of 100% compared to the previous 30 days.

Company Ownership

• Score: 0.8 / 5
• Insider Trading: Selling Shares

Insider Buying vs. Insider Selling

In the past three months, Mind Medicine (MindMed) insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $311,644.00 in company stock.

Percentage Held by Insiders

Only 2.26% of the stock of Mind Medicine (MindMed) is held by insiders.

Percentage Held by Institutions

Only 27.91% of the stock of Mind Medicine (MindMed) is held by institutions.

MNMD Stock Analysis - Frequently Asked Questions

How have MNMD shares performed this year?

Mind Medicine (MindMed)'s stock was trading at $6.96 at the start of the year. Since then, MNMD shares have increased by 11.3% and is now trading at $7.7450.

How were Mind Medicine (MindMed)'s earnings last quarter?

Mind Medicine (MindMed) Inc. (NASDAQ:MNMD) announced its quarterly earnings results on Thursday, May, 8th. The company reported ($0.35) earnings per share (EPS) for the quarter, beating analysts' consensus estimates of ($0.36) by $0.01.
Read the conference call transcript.

When did Mind Medicine (MindMed)'s stock split?

Mind Medicine (MindMed)'s stock reverse split before market open on Monday, August 29th 2022.The 1-15 reverse split was announced on Monday, August 29th 2022. The number of shares owned by shareholders was adjusted after the closing bell on Monday, August 29th 2022. An investor that had 100 shares of stock prior to the reverse split would have 7 shares after the split.

How do I buy shares of Mind Medicine (MindMed)?

Shares of MNMD stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

What other stocks do shareholders of Mind Medicine (MindMed) own?

Based on aggregate information from My MarketBeat watchlists, some other companies that Mind Medicine (MindMed) investors own include NVIDIA (NVDA), Meta Platforms (META), Advanced Micro Devices (AMD), CrowdStrike (CRWD), Tesla (TSLA) and

Company Calendar

• Last Earnings: 5/08/2025
• Today: 7/09/2025
• Next Earnings (Estimated): 8/12/2025
• Fiscal Year End: 12/31/2025

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Medical
• Industry: MED - BIOMED/GENE
• Sub-Industry: Pharmaceutical Products
• Current Symbol: NASDAQ:MNMD
• CIK: 1813814
• Web: www.mindmed.co
• Phone: 650-208-2454
• Fax: N/A
• Employees: 40
• Year Founded: N/A

Price Target and Rating

• Average Price Target for Mind Medicine (MindMed): $25.50
• High Price Target: $55.00
• Low Price Target: $14.00
• Potential Upside/Downside: +241.4%
• Consensus Rating: Buy
• Rating Score (0-4): 3.27
• Research Coverage: 11 Analysts

Profitability

• EPS (Trailing Twelve Months): ($1.29)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: -$108.68 million
• Net Margins: N/A
• Pretax Margin: N/A
• Return on Equity: -40.33%
• Return on Assets: -32.13%

Debt

• Debt-to-Equity Ratio: 0.10
• Current Ratio: 7.27
• Quick Ratio: 7.27

Sales & Book Value

• Annual Sales: N/A
• Price / Sales: N/A
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: $3.21 per share
• Price / Book: 2.33

Miscellaneous

• Outstanding Shares: 75,550,000
• Free Float: 73,846,000
• Market Cap: $564.36 million
• Optionable: Optionable
• Beta: 2.45